1. Shenzhen Yike Pharmaceutical Holding Co., Ltd.
Shareholding ratio: 65,438+03,65,438+0,778,300 shares. Shareholding ratio: 66.32%.
Two. Shenzhen Hengjian Enterprise Management Partnership Corporation (Limited Partnership)
Number of shares held: 9,230,800 shares. Shareholding ratio: 4.65%.
Three. Shenzhen Yuzao Enterprise Management Partnership (Limited Partnership)
Shareholding ratio: 80 1.62 million shares. Shareholding ratio: 4.03%.
Four. Changjiang Fortune-Kexing Pharmaceutical Staff Strategic Resettlement Collective Asset Management Plan
Number of shares held: 4,967,500 shares. Shareholding ratio: 2.50%.
Verb (abbreviation of verb) CITIC Construction Investment Co., Ltd.
Shareholding: 822,400 shares. Shareholding ratio: 0.4 1%.
6. Li Yonggang
Shareholding: 800,000 shares. Shareholding ratio: 0.40%.
Seven. Tianjian Quantification (Beijing) Capital Management Co., Ltd.-Tianjian Exclusive Private Equity Investment FundNo. 12
Number of shares held: 478,700 shares. Shareholding ratio: 0.24%.
Eight, Wang Jianyu
Number of shares held: 336,900 shares. Shareholding ratio: 0. 17%.
9. Shenzhen Li Runze Investment Co., Ltd.
Shareholding: 308,600 shares. Shareholding ratio: 0. 16%.
X. Shu Jie
Shareholding ratio: 2,965,438+0.7 million shares. Shareholding ratio: 0. 15%.
Kexing Biopharmaceutical Co., Ltd. is an innovative biopharmaceutical enterprise, mainly engaged in the production and sales of R&D, recombinant protein drugs and microecological agents. Founded on August 22nd, 1997, its headquarters is located in Zhangqiu District, Jinan City, Shandong Province.
The company focuses on drug research and development in the fields of antivirus, tumor and immunity, hematology, digestion and degenerative diseases. , and successfully landed on the A-share Science and Technology Innovation Board in June 5438+February 65438+April 2020 with the stock code 688 136.
In February of 2002165438, Kexing Bio published the unaudited financial report for the first half of 20021,and the sales in the first half of 2002 1 1 billion dollars and the net profit was 5 1 billion dollars.
The company has built a complete drug R&D innovation system, covering drug innovation ability from drug discovery, drug research, preclinical research, clinical research to industrialization. It has three technical systems: prokaryotic cell technology, eukaryotic cell technology and microecological viable bacteria technology, and has successfully built five leading technical platforms at home and abroad, such as strain technology platform, recombinant protein drug industrialization technology platform, microecological agent R&D and industrialization technology platform, recombinant protein secretion and expression technology platform and recombinant protein long-term technology platform.
In 20 17, the company's technology center was recognized as "Shandong Enterprise Technology Center", in 20 18, it was recognized as "Jinan protein Pharmaceutical Engineering Laboratory", and in 2020, it was recognized as "Guangdong protein Pharmaceutical Engineering Center for Genetic Engineering Reorganization", "Shandong protein Pharmaceutical Engineering Laboratory" and "Shenzhen Postdoctoral Innovation Practice Base". The company has obtained 38 patents and 9 biopharmaceutical projects under research, including 3 bio-innovative drugs.